Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Crescent Sterling Ltd.

Crescent Sterling Ltd. boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,819 shares of the medical instruments supplier’s stock after buying an additional 145 shares during the quarter. Crescent Sterling Ltd.’s holdings in Becton, Dickinson and Company were worth $945,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. CX Institutional grew its position in shares of Becton, Dickinson and Company by 3.0% in the third quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock valued at $385,000 after purchasing an additional 43 shares during the period. U.S. Capital Wealth Advisors LLC grew its position in shares of Becton, Dickinson and Company by 3.4% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock valued at $339,000 after purchasing an additional 43 shares during the period. Valeo Financial Advisors LLC grew its position in shares of Becton, Dickinson and Company by 8.4% in the third quarter. Valeo Financial Advisors LLC now owns 3,177 shares of the medical instruments supplier’s stock valued at $821,000 after purchasing an additional 246 shares during the period. Golden State Equity Partners grew its position in shares of Becton, Dickinson and Company by 6.1% in the third quarter. Golden State Equity Partners now owns 1,564 shares of the medical instruments supplier’s stock valued at $404,000 after purchasing an additional 90 shares during the period. Finally, Bfsg LLC grew its position in shares of Becton, Dickinson and Company by 7.9% in the third quarter. Bfsg LLC now owns 25,977 shares of the medical instruments supplier’s stock valued at $6,716,000 after purchasing an additional 1,894 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on BDX shares. Raymond James raised their price target on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Barclays raised their price target on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Trading Up 0.5 %

Shares of Becton, Dickinson and Company stock traded up $1.16 on Tuesday, reaching $234.60. The company had a trading volume of 1,624,484 shares, compared to its average volume of 1,365,751. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.64 and a current ratio of 1.08. The firm has a market cap of $67.78 billion, a PE ratio of 55.59, a PEG ratio of 1.91 and a beta of 0.43. The firm’s 50 day moving average price is $238.98 and its two-hundred day moving average price is $240.76. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.98 earnings per share. Sell-side analysts predict that Becton, Dickinson and Company will post 12.94 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a dividend of $0.95 per share. This represents a $3.80 annualized dividend and a yield of 1.62%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 90.05%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.31% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.